Glumetza is a drug owned by Santarus Inc. It is protected by 6 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 23, 2025. Details of Glumetza's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US7780987 | Controlled release dosage forms |
Mar, 2025
(a month ago) |
Expired
|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8323692 | Controlled release dosage forms |
Mar, 2025
(a month ago) |
Expired
|
| US6723340 | Optimal polymer mixtures for gastric retentive tablets |
Oct, 2021
(3 years ago) |
Expired
|
| US6488962 | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
Jun, 2020
(4 years ago) |
Expired
|
| US6340475 | Extending the duration of drug release within the stomach during the fed mode |
Sep, 2016
(8 years ago) |
Expired
|
| US6635280 | Extending the duration of drug release within the stomach during the fed mode |
Sep, 2016
(8 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Glumetza's patents.
Latest Legal Activities on Glumetza's Patents
Given below is the list of recent legal activities going on the following patents of Glumetza.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 26 Jan, 2022 | US7780987 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 04 Jun, 2020 | US8323692 |
| Review Certificate Mailed | 26 Jul, 2018 | US6723340 (Litigated) |
| Review Certificate | 09 Jul, 2018 | US6723340 (Litigated) |
| Review Certificate Mailed | 09 Feb, 2018 | US6635280 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 02 Feb, 2018 | US7780987 (Litigated) |
| Review Certificate | 14 Dec, 2017 | US6635280 |
| File Marked Found | 25 Apr, 2016 | US6723340 (Litigated) |
| File Marked Found | 18 Feb, 2016 | US6723340 (Litigated) |
| File Marked Found | 12 Feb, 2016 | US6723340 (Litigated) |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Glumetza and ongoing litigations to help you estimate the early arrival of Glumetza generic.
Glumetza's Litigations
Glumetza been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 17, 2014, against patent number US6723340. The petitioner Endo Pharmaceutical Inc. et al., challenged the validity of this patent, with DepoMed, Inc. as the respondent. Click below to track the latest information on how companies are challenging Glumetza's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6340475 | April, 2014 |
Final Written Decision
(21 Sep, 2015) | Depomed, Inc. | Endo Pharmaceutical Inc. et al. |
| US6635280 | April, 2014 |
Final Written Decision
(21 Sep, 2015) | Depomed, Inc. | Endo Pharmaceutical Inc. et al. |
| US6723340 | April, 2014 |
Final Written Decision
(16 Sep, 2015) | DepoMed, Inc. | Endo Pharmaceutical Inc. et al. |
| US6340475 | January, 2014 |
FWD Entered
(08 Jul, 2015) | Depomed, Inc. | Purdue Pharma L.P. |
| US6635280 | January, 2014 |
FWD Entered
(08 Jul, 2015) | DepoMed, Inc. | Purdue Pharma L.P. |
| US6340475 | April, 2014 |
Institution Denied
(29 Sep, 2014) | Depomed, Inc. | Endo Pharmaceutical Inc. et al. |
| US6635280 | April, 2014 |
Institution Denied
(29 Sep, 2014) | Depomed, Inc. | Endo Pharmaceutical Inc. et al. |
| US6723340 | April, 2014 |
Institution Denied
(29 Sep, 2014) | DepoMed, Inc. | Endo Pharmaceutical Inc. et al. |
US patents provide insights into the exclusivity only within the United States, but Glumetza is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Glumetza's family patents as well as insights into ongoing legal events on those patents.
Glumetza's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Glumetza's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 23, 2025 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Glumetza Generic API suppliers:
Metformin Hydrochloride is the generic name for the brand Glumetza. 69 different companies have already filed for the generic of Glumetza, with Apotex having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Glumetza's generic
How can I launch a generic of Glumetza before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Glumetza's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Glumetza's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Glumetza -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 500 mg and 1000 mg | 27 Jul, 2009 | 1 | 19 Jul, 2013 | Eligible |
Alternative Brands for Glumetza
Glumetza which is used for managing Type II diabetes., has several other brand drugs using the same active ingredient (Metformin Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||||
|---|---|---|---|---|---|---|
| Andrx Labs Llc |
| |||||
| Astrazeneca Ab |
| |||||
| Boehringer Ingelheim |
| |||||
| Bristol Myers Squibb |
| |||||
| Emd Serono Inc |
| |||||
| Janssen Pharms |
| |||||
| Msd Sub Merck |
| |||||
| Novo Nordisk Inc |
| |||||
| Ranbaxy |
| |||||
| Sb Pharmco |
| |||||
| Sun Pharm |
| |||||
| Takeda Pharms Usa |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Metformin Hydrochloride, Glumetza's active ingredient. Check the complete list of approved generic manufacturers for Glumetza
About Glumetza
Glumetza is a drug owned by Santarus Inc. It is used for managing Type II diabetes. Glumetza uses Metformin Hydrochloride as an active ingredient. Glumetza was launched by Santarus Inc in 2005.
Approval Date:
Glumetza was approved by FDA for market use on 03 June, 2005.
Active Ingredient:
Glumetza uses Metformin Hydrochloride as the active ingredient. Check out other Drugs and Companies using Metformin Hydrochloride ingredient
Treatment:
Glumetza is used for managing Type II diabetes.
Dosage:
Glumetza is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1GM | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 500MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |